Washington, DCThe first new treatment for the disease lupus in half a century recently received US Food and Drug Administration (FDA) approval and is expected to significantly aid GlaxoSmithKline sales, Reuters reports.
According to the news source, the FDA decided to approve Benlysta, which was discovered by Human Genome Sciences Inc. as a means of battling the disease, which reportedly causes the immune system to inflict damage upon organs and joints.
The company is reportedly expected to split profits with GlaxoSmithKline, a UK-based drug firm. The drug's global sales could exceed $3 billion in 2015, according to forecasts by the news provider. Sales could ultimately reach $5 billion in future years, some analysts believe.
"It is a big success. It opens the way for more FDA-approved lupus drugs," Dr. Anca Askanase of the New York University School of Medicine told the news source.
The approval represents a positive sign for sales representatives at GlaxoSmithKline, particularly after the US Supreme Court recently left in place a decision that said pharmaceutical sales reps can receive overtime pay, according to the Wall Street Journal.
If you or a loved one have suffered losses in this case, please click the link below and your complaint will be sent to a drugs & medical lawyer who may evaluate your GSK Sales Rep California Overtime claim at no cost or obligation.